Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., … Armstrong, A. J. (2024). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.09.005
Authors:
Dana E. Rathkopf
Manish R. Patel
Atish D. Choudhury
Drew W. Rasco
Nehal J. Lakhani
Jessica E. Hawley
S. Srinivas
Ana Aparicio
Vivek Narayan
Karie Runcie
Hamid Emamekhoo
Zachery R. Reichert
Minh Nguyen
Alan Wells
Raju Kandimalla
Chun‐Yu Liu
S Suryawanshi
Jing Han
Jiwen Wu
Vinod Arora
Michael Pourdehnad
Andrew J. Armstrong
Affiliated Authors:
Karie Runcie
Author Keywords:
mcrpc
ligand-directed degrader
androgen receptor pathway inhibitor
androgen receptor antagonist
ligand binding domain
protein degradation
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2024.09.005
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: